|
|
|
Skin rejuvenation
Over the past year Aus Bio has continued commercial discussions with pharma companies regarding development and commercialisation of the Company’s MD 920 "Advanced Wound Care Programme". Read more.
|
|
|
Welcome to AusBio Limited
Aus Bio Ltd. is a public but unlisted, Melbourne based biotechnology company.
Aus Bio’s current research and management philosophy is to focus on identifying chronic disease states where:
- large markets exist
- new and improved treatments are required.
Dual Mission
- to discover, develop and commercialise new pharmaceuticals that benefit mankind
- to increase shareholder value.
Research
To this end, the company is currently developing new treatments for:
- MD 920 / 921 – The Development of Advanced Wound Care Product(s)
- MD 920G – Glaucoma and Intraocular Pressure
- MD 922 – Cosmetics and Skin Health
- MD 960 – Diabetes / Insulin Resistance
- MD 2009 - “Influenza”, The Development of Next Generation Anti Virals
- MD 990 – The Development of Novel Pharmaceuticals for Specific Acute and Chronic Respiratory Conditions
- MD 2001 – The Development of Anti Infective & Inflammatory Bowel Disease
- PC 2000 – The Development of Novel Pharmaceuticals for Specific Acute and Chronic Respiratory Conditions
|
|
|
|
